Division of Cardiology, Department of Medicine, , Cardiovascular Institute, University of California San Diego, La Jolla, California, USA.
Pacing Clin Electrophysiol. 2022 Jul;45(7):853-860. doi: 10.1111/pace.14519. Epub 2022 Jun 1.
Limited data exists for outcomes in patients undergoing cardiovascular implantable electronic device (CIED) transvenous lead extraction (TLE) without clear indications for device reimplantation. The implantable loop recorder (ILR) may be an effective strategy for continuous monitoring in select individuals.
This retrospective analysis aims to investigate patients who have undergone ILR implant following TLE without CIED reimplantation.
Clinical data from consecutive patients who have undergone TLE with ILR implant and without CIED reimplantation from October 2016 to May 2020 at a single center were collected.
Among 380 patients undergoing TLE, 28 (7.7%) underwent ILR placement without CIED reimplantation. TLE indications were systemic infection (n = 13, 46.4%), pain at the site (n = 8, 28.6%), device/lead malfunction (n = 4, 14.2%), and other. Devices extracted included: dual-chamber and single-chamber pacemaker (n = 14, 50%; n = 4, 14.2%), dual-chamber implantable cardiac defibrillator (n = 10; 35.7%), and cardiac-resynchronization therapy with defibrillator (n = 1, 3.5%). Reasons for no reimplantation included no longer meeting CIED criteria (n = 14, 50%), patient preference (n = 9, 32.1%), and no clear or inappropriate indication for initial CIED implantation (n = 5, 18%). During an average of 12.3 ± 13.1 months of follow-up, there were no lethal arrhythmias, and four (13.3%) patients underwent permanent pacemaker reimplantation due to symptomatic sinus bradycardia and atrioventricular block with syncope as discovered on ILR. Three patients died due to unknown causes (n = 1), noncardiac (n = 1), and acute coronary syndrome (n = 1).
In patients undergoing TLE without reimplantation, an ILR may be an effective monitoring strategy in patients at low risk for cardiac arrhythmia.
对于没有明确植入式心脏电子设备(CIED)再植入适应证的心血管植入式电子设备(CIED)经静脉导线拔除(TLE)患者的结局,相关数据有限。植入式环路记录器(ILR)可能是选择患者进行连续监测的有效策略。
本回顾性分析旨在研究 TLE 后行 ILR 植入而未行 CIED 再植入的患者。
连续收集 2016 年 10 月至 2020 年 5 月在一家单中心行 TLE 并同时行 ILR 植入而未行 CIED 再植入的患者的临床数据。
在 380 例行 TLE 的患者中,有 28 例(7.7%)在未行 CIED 再植入的情况下行 ILR 植入。TLE 的适应证包括全身感染(n=13,46.4%)、植入部位疼痛(n=8,28.6%)、器械/导线故障(n=4,14.2%)和其他原因。所取出的器械包括:双腔和单腔起搏器(n=14,50%;n=4,14.2%)、双腔植入式心脏除颤器(n=10,35.7%)和心脏再同步治疗除颤器(n=1,3.5%)。不进行再植入的原因包括不再符合 CIED 标准(n=14,50%)、患者意愿(n=9,32.1%)和最初 CIED 植入无明确或不适当适应证(n=5,18%)。在平均 12.3±13.1 个月的随访中,无致死性心律失常发生,4 例(13.3%)患者因 ILR 发现症状性窦性心动过缓、房室传导阻滞伴晕厥而再次行永久起搏器植入。3 例患者死亡,死因分别为不明原因(n=1)、非心脏原因(n=1)和急性冠状动脉综合征(n=1)。
在未行再植入的 TLE 患者中,ILR 可能是低心律失常风险患者的一种有效监测策略。